文献速递贫血与红细胞疾病

重型/极重型再生障碍性贫血患者的红细胞寿命

[The life span of red blood cell in patients with severe/very severe aplastic anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

回顾性分析128例SAA/VSAA患者及13名健康对照,采用内源性一氧化碳呼气试验检测红细胞寿命。初诊未治患者红细胞平均寿命较正常对照明显缩短,免疫抑制治疗后改善或恢复正常,细胞因子升高可能与红细胞寿命缩短有关。

要点

  • 初诊未治SAA/VSAA患者红细胞平均寿命(50.69±21.43)d,较正常对照(111.85±31.55)d明显缩短。
  • IST后获得HR者红细胞寿命较初诊和NR者明显延长,与正常对照接近;CR者与正常对照差异无统计学意义。
  • HR患者血清IL-2R及IL-6较NR患者明显减低,细胞因子升高可能与红细胞寿命缩短有关。

核心结论

  • SAA/VSAA患者红细胞寿命缩短,IST后可改善或恢复正常。
  • 淋巴细胞因子水平升高可能与SAA/VSAA红细胞寿命缩短有关。

研究设计与样本

  • 回顾性分析2016年11月至2017年4月128例SAA/VSAA患者临床资料,以同期13名健康志愿者为正常对照。
  • 采用内源性一氧化碳呼气试验法检测红细胞寿命,观察IST对红细胞寿命的影响。

主要发现

  • 51例初诊未治SAA/VSAA患者红细胞平均寿命为(50.69±21.43)d,较正常对照(111.85±31.55)d明显缩短(t=-6.611,P<0.001)。
  • 77例IST组患者红细胞平均寿命为(87.14±39.28)d,其中CR、HR、NR患者分别为(106.15±32.12)d、(92.00±38.60)d、(50.44±21.56)d。
  • HR患者红细胞平均寿命较初诊者延长(t=7.430,P<0.001),较NR者延长(t=4.846,P=0.002),与正常对照接近(t=-1.743,P=0.085)。
  • CR患者红细胞平均寿命与正常对照差异无统计学意义(t=-0.558,P=0.579)。
  • 单因素分析未发现影响初诊SAA/VSAA患者红细胞寿命的因素。

关键数值与推荐

  • HR患者与NR患者相比,血清IL-2R为4.3(1.2~9.7)×10⁵ U/L vs 6.5(3.7~44.1)×10⁵ U/L(z=-2.733,P=0.006),HR组低于NR组。
  • HR患者与NR患者相比,血清IL-6为2.6(2.0~17.7)ng/L vs 6.1(2.0~14.4)ng/L(z=-2.968,P=0.003),HR组低于NR组。
  • 初诊组51例中38例后续接受IST并评价3个月疗效,ROC曲线分析治疗前红细胞寿命对IST疗效的预测作用,界值为60 d,敏感性37.5%、特异性86.4%。
  • 治疗前红细胞寿命>60 d者9例中6例获得HR,≤60 d者29例中10例获得HR,差异无统计学意义(P=0.128)。

临床怎么用

  • 初诊SAA/VSAA患者红细胞寿命缩短,IST后可改善或恢复正常。
  • 作者认为淋巴细胞因子水平升高可能与SAA/VSAA红细胞寿命缩短有关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the life span of red blood cells (RBC) in patients with severe/very severe aplastic anemia (SAA/VSAA). Methods: Clinical data of 128 SAA/VSAA patients from November 2016 to April 2017 were retrospectively analyzed, and 13 healthy volunteers in the same period was used as normal control. The endogenous Breath Carbon Monoxide (CO) test was used to detect the life span of RBC in SAA/VSAA patients, and the effect of immunosuppressive therapy (IST) on the life span of RBC in these patients was explored. Results: The mean life span of RBC in 51 untreated SAA/VSAA patients was (50.69±21.43) d, which was significantly shorter than that in normal controls[(111.85±31.55) d](t=-6.611, P<0.001). The mean life span of RBC in 77 patients treated with IST was (87.14±39.28) d. The mean life span of RBC in complete responses (CR), hematologic response (HR) and non-response (NR) patients were (106.15±32.12) d, (92.00±38.60) d and (50.44±21.56) d, respectively. The life span of RBC in patients with HR was significantly longer than that in newly diagnosed and NR patients (t=7.430, P<0.001; t=4.846, P=0.002), which was similar to that in the normal controls (t=-1.743,P=0.085). There was no statistical significance between CR patients and the normal controls in the mean life span of RBC (t=-0.558, P=0.579). No factor affecting the RBC life span was found in univariate logistical regression analyses in the newly diagnosed SAA/VSAA patients. The serum levels of IL-2R and IL-6 were much lower in HR patients than NR patients[IL-2R: 4.3×105 U/L vs 6.5×105 U/L, z=-2.733, P=0.006; IL-6: 2.6 (2.0-17.7) ng/L vs 6.1 (2.0-14.4) ng/L, z=-2.968, P=0.003]. Of the 51 newly diagnosed patients, 38 received IST and their 3-month curative effect was evaluated. Receiver operator characteristics (ROC) curve was used to analyze the predictive effect of RBC life span of untreated patients on the efficacy of IST before treatment. The cut-off point was 60 days with sensitivity of 37.5% and specificity of 86.4%. In 9 cases with life span of RBC>60 d before IST, 6 cases acquired HR, while in 29 cases with life span of RBC ≤ 60 d before IST, 10 cases acquired HR, the difference was not statistically significant (P=0.128). Conclusion: The life span of RBC in SAA/VSAA patients was shortened, which can be improved even recovered to the normal after IST. Elevated cytokines might play a role in the pathophysiology of the shortened RBC life span in SAA/VSAA. 目的: 研究重型/极重型再生障碍性贫血(SAA/VSAA)患者的红细胞寿命。 方法: 回顾性分析2016年11月至2017年4月128例SAA/VSAA患者临床资料,以同期13例健康志愿者为正常对照。采用测定内源性一氧化碳呼气试验法检测红细胞寿命,观察SAA/VSAA患者红细胞寿命是否改变及免疫抑制治疗(IST)对红细胞寿命的影响。 结果: 51例初诊未治SAA/VSAA患者红细胞平均寿命为(50.69±21.43)d,较正常对照者[(111.85±31.55)d]明显缩短(t=-6.611,P<0.001)。77例IST组患者红细胞平均寿命为(87.14±39.28)d,其中获得完全治疗反应(CR)、获得治疗反应(HR)、未获治疗反应(NR)患者红细胞平均寿命分别为(106.15±32.12)、(92.00±38.60)、(50.44±21.56)d。获得HR患者红细胞平均寿命较初诊和NR者明显延长(t=7.430,P<0.001;t=4.846,P=0.002),与正常健康对照者接近(t=-1.743,P=0.085);获得CR患者红细胞平均寿命与正常对照者差异无统计学意义(t=-0.558,P=0.579)。单因素分析未发现影响初诊SAA/VSAA患者红细胞寿命的因素。获得HR的患者与NR患者相比,血清IL-2受体[4.3(1.2~9.7)×105 U/L对6.5(3.7~44.1)×105 U/L,z=-2.733,P=0.006]及IL-6[2.6(2.0~17.7)ng/L对6.1(2.0~14.4)ng/L,z=-2.968,P=0.003]明显减低。初诊组51例患者中38例后续接受IST并评价3个月疗效。采ROC曲线分析治疗前患者红细胞寿命对IST疗效的预测作用,其界值为60 d(敏感性和特异性分别为37.5%和86.4%)。9例治疗前红细胞寿命>60 d患者6例获得HR,29例治疗前红细胞寿命≤60 d患者10例获得HR,差异无统计学意义(P=0.128)。 结论: SAA/VSAA患者红细胞寿命缩短,IST后可改善或恢复正常。淋巴细胞因子水平升高可能与SAA/VSAA红细胞寿命缩短有关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ye L, Guo J, Jing LP, et al. [The life span of red blood cell in patients with severe/very severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562449. doi:10.3760/cma.j.issn.0253-2727.2018.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。